Verastem Inc. (VSTM)
Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High?
The mean of analysts' price targets for Verastem (VSTM) points to a 159.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript
Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates
Verastem (VSTM) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $1.33 per share a year ago.
What Makes Verastem (VSTM) a New Buy Stock
Verastem (VSTM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results
VSTM shares rise nearly 8% after the release of preliminary fourth-quarter 2025 and full-year 2025 sales numbers, driven by Avmapki Fakzynja Co-pack.
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC
Verastem, Inc. is downgraded from Strong Buy" to Buy following discontinuation of its RAMP-203 G12C NSCLC study. VSTM pivots focus to VS-7375, an oral KRAS G12D "ON/OFF" inhibitor, with promising early efficacy and safety data in KRAS G12D NSCLC patients. Upcoming interim phase 1/2a U.S. data for VS-7375 in KRAS G12D solid tumors, expected 1H 2026, is a major catalyst.
Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript
Verastem, Inc. ( VSTM ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Julissa Viana - Vice President of Corporate Communications & Investor Relations Daniel Paterson - President, CEO & Director Matthew Ros - Chief Operating Officer Michael Crowther - Chief Commercial & Strategy Officer Daniel Calkins - Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Justin Zelin - BTIG, LLC, Research Division Xun Lee - H.C. Wainwright & Co, LLC, Research Division Yuan Zhi - B.
Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates
Verastem (VSTM) came out with a quarterly loss of $1.35 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.6 per share a year ago.
Verastem (VSTM) Upgraded to Buy: Here's Why
Verastem (VSTM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice
Does Verastem (VSTM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript
Verastem, Inc. (NASDAQ:VSTM ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Daniel Calkins - Chief Financial Officer Daniel W. Paterson - President, CEO & Director Julissa Viana - Vice President of Corporate Communications & Investor Relations Matthew E.
Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates
Verastem (VSTM) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.31 per share a year ago.
